Opsona Therapeutics

Opsona Therapeutics

Founded	1 January 2004
Headquarters	Dublin   , Republic of Ireland
Website	www.opsona.com

Opsona Therapeutics was a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. ^{[1] [2] [3]}

Based in Ireland, Opsona was a spin-out from Trinity College Dublin (TCD). ^[4] Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field. ^[5]

Opsona's research was primarily focused on the role of Toll-like receptors (TLRs) and TLR signalling in human innate immunity. The company was founded in 2004 by three immunologists:

• Professor Luke O'Neill ^[6]
• Professor Kingston Mills ^[7]
• Professor Dermot P. Kelleher ^[8]

The company went into liquidation in 2019 after unsuccessful clinical trials, and failure to find a buyer for OPN-305.

Opsona's main investors were international and life-science focused:

• Inventages Venture Capital (Bahamas) ^[9]
• Seroba Bioventures (Ireland)
• GenenFund (United States)
• Enterprise Ireland (Ireland) ^[10]

References

1. "Ireland's got talent" . Retrieved 27 February 2018.
2. "Sunday Business Post article" . Retrieved 27 February 2018.
3. "Opsona Therapeutics Limited: Private Company Information - Bloomberg". investing.businessweek.com. Archived from the original on September 10, 2012. Retrieved 27 February 2018.
4. "Emerging finalist: Mark Heffernan Opsona Therapeutics" . Retrieved 27 February 2018.
5. Times Higher Education Supplement - QS World University Rankings 2007
6. "Trinity team makes vaccine discovery". 4 May 2009. Retrieved 27 February 2018.
7. "Kingston Mills - Research : School of Biochemistry and Immunology : Trinity College Dublin, the University of Dublin, Ireland". www.tcd.ie. Retrieved 27 February 2018.
8. "Article on the Trinity College Dublin website" . Retrieved 27 February 2018.
9. "Opsona Therapeutics Closes EUR18M Funding - FierceBiotech". www.fiercebiotech.com. Retrieved 27 February 2018.
10. "PR Newswire article" . Retrieved 27 February 2018.